AbstractAimsTo evaluate the effect of spinal interventions following ISIS guidelines .MethodsData from all patients from April 2012 until February 2014 have been registered and followed up after 4–6 months. Patients were mainly referred from surgeons at the regional hospitals. Employment status, medication, VAS, EQ-5D-5L, EQ-VAS and pain reduction were gathered before and at the follow-up. Only patients receiving any kind of treatment were included.ResultsSo far 419/823 patients have been followed-up. Here we present levels of medication and total pain reduction for all patients and, separately, for patients treated with radio frequency facet joint medial branch neurotomy (n = 76).Opioids were reduced from 33% to 26% and no use of analgesics increased from 15% to 31% (p < 0.0159). Opioids in the RF group fell from 31% to 21%, and no use went from 2% to 31%. Of all the patients, 46% had pain reduction >50% and 9% were pain free. In the RF group the figures were 57% and 11%, respectively. No one in the RF group got worse.ConclusionIt is important to follow-up your results, even if complete scientific RCT rigour cannot be upheld Our stringent, long-term follow-up can presumably deliver reasonably reliable effect information, a majority of our patients have reduced their medication significantly (p < 0.001) and more than 50% experience a greater than 50% pain reduction, indicating a significant effect.
Scandinavian Journal of Pain – de Gruyter
Published: Dec 29, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera